Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
Prescribing Information
For details of the enhanced Pregnancy Prevention Programme, please click on the prescribing information links below.
PHESGO Expert Exchange is a promotional video series produced by Roche in collaboration with Breast Oncologists. Designed to bring expert’s insights on trial data and PHESGO in clinical practice with real world patients case studies. Watch the videos below to hear Oncologists Dr Mukesh & Dr Okines discuss PHESGO and its impact on UK clinical practice. Always refer to the PHESGO Summary of Product Characteristics (UK) before treating a patient.
Explore resources
If viewing on mobile, for best viewing experience please rotate your phone to landscape mode.
Listen as Dr. Mukesh and Dr. Okines provide expert insights into the long-term management of HER2-positive mBC with PHESGO.
Abbreviations: 1L: First Line; eBC: Early Breast Cancer; HER2: Human epidermal growth factor receptor 2; mBC: Metastatic Breast Cancer
Metastatic Breast Cancer (mBC)
PHESGO is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
The Experts
PHESGO is a fixed-dose combination of pertuzumab and trastuzumab in one vial for subcutaneous use given every 3 weeks1
In patients receiving a taxane, PHESGO should be administered prior to the taxane.
* Patients should be observed for injection-related reactions and hypersensitivity reactions. Observation period should start following administration of PHESGO and be completed prior to any subsequent administration of chemotherapy1
Once pertuzumab-based therapy has been safely established, the physician may determine the suitability of administration of PHESGO outside of the clinical setting (e.g., at home) by a healthcare professional (see SmPC section 4.4).1
Prefer to talk things through? We’re here to speak with you about supporting your HER2+ eBC patients
Connect with our team
Reference:
- PHESGO Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11989/smpc